| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $35.7M | +94.8% |
| SG&A Expense | $18.4M | +104.1% |
| Operating Income | -$54.1M | -97.9% |
| Net Income | -$50.6M | -85.3% |
| EPS (Basic) | -$1.31 | +53.9% |
| EPS (Diluted) | -$1.31 | +53.9% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $94.6M | -61.3% |
| Total Assets | $222.4M | -11.4% |
| Current Liabilities | $11.1M | +202.4% |
| Total Liabilities | $14.8M | +230.0% |
| Stockholders' Equity | $207.6M | -15.8% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$32.9M | -21.2% |
| Capital Expenditures | $455K | — |
| Investing Cash Flow | -$117.3M | — |
| Financing Cash Flow | $182K | -99.9% |
| Free Cash Flow | -$33.4M | — |